Walking Fish Therapeutics Launches with $50 Million in Series A Financing to Accelerate Development of B Cell Therapies for Multiple Diseases

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Walking Fish Therapeutics, a leader in B cell engineering, today announced the close of $50M Series A financing— led by investors including Emerson Collective, Illumina Ventures and Quan Capital— to develop B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production. Walking Fish Therapeutics has made critical advances in developing a platform to harness B cells’ capability to activa
Click here to view original post